4//SEC Filing
QUAY STEVEN C 4
Accession 0001615774-18-004657
CIK 0001488039other
Filed
May 30, 8:00 PM ET
Accepted
May 31, 3:26 PM ET
Size
9.0 KB
Accession
0001615774-18-004657
Insider Transaction Report
Form 4
QUAY STEVEN C
DirectorCEO10% Owner
Transactions
- Purchase
Series B Convertible Preferred Stock
2018-05-30$1000.00/sh+8$8,000→ 8 total(indirect: See footnote)Exercise: $3.52From: 2018-05-30→ Common Stock (2,273 underlying) - Purchase
Warrants
2018-05-30$1000.00/sh+2,272$2,272,000→ 2,272 total(indirect: See footnote)Exercise: $4.05From: 2018-05-30Exp: 2022-05-30→ Common Stock (2,272 underlying)
Footnotes (5)
- [F1]Each share of Series B Convertible Preferred Stock is convertible into the number of shares of Common Stock equal to the stated value of $1,000 divided by $3.52.
- [F2]Shares of Series B Convertible Preferred Stock do not expire.
- [F3]No fractional shares will be issued upon conversion. At its election, the Company will either issue a cash adjustment or round up to the next whole share. The number reflected here assumes rounding up to the next whole share.
- [F4]Shares of Series B Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series B Convertible Preferred Stock and 284 Warrants.
- [F5]Securities are owned by Ensisheim Partners, LLC ("Ensisheim"). Shu-Chih Chen, Ph.D. and Steven C. Quay, M.D., Ph.D., share voting and investment power over the securities held by Ensisheim. Ensisheim is solely owned and controlled by Drs. Chen and Quay, and, as a result, Drs. Chen and Quay are deemed to be beneficial owners of the shares held by this entity.
Documents
Issuer
ATOSSA GENETICS INC
CIK 0001488039
Entity typeother
Related Parties
1- filerCIK 0001008227
Filing Metadata
- Form type
- 4
- Filed
- May 30, 8:00 PM ET
- Accepted
- May 31, 3:26 PM ET
- Size
- 9.0 KB